---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-027442"
form_type: "8-K"
ticker: "APRE"
cik: "0001781983"
company_name: "Aprea Therapeutics, Inc."
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T18:33:10.824090+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aprea Therapeutics regains Nasdaq minimum bid price compliance

## Summary
- Received Nasdaq deficiency letter on Sept 12, 2022 for bid price below $1.00.
- Regained compliance on March 1, 2023 after 10 consecutive trading days above $1.00 (Feb 14-28).
- CEO Oren Gilad cited recent financing and progress on clinical asset ATRN-119 and pre-clinical ATRN-W1051.

## SEC filing metadata
- accession: 0001104659-23-027442
- form_type: 8-K
- ticker: APRE
- cik: 0001781983
- company_name: Aprea Therapeutics, Inc.
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781983/000110465923027442/0001104659-23-027442-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781983/000110465923027442/tm238260d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-027442
- JSON: https://secwatch.observer/filing/0001104659-23-027442.json
- Plain text: https://secwatch.observer/filing/0001104659-23-027442.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.